Answers are grounded in this paper and cite their sources.
Last week, the Food and Drug Administration (FDA) voted 9‐2 to reject the application of Lykos Therapeutics, the newly formed commercial arm of MAPS, for “midomafetamine” (actually MDMA, or methylenedioxymethamphetamine) to treat post‐traumatic stress disorder (PTSD).
No takes yet. Share an insight, caveat, or question.
Alison Knopf (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: